All sales were pre-arranged under 10b5-1 plans and are small relative to market cap, so they do not signal a change in outlook. The derivative exercises at $72.68 and immediate sales at ~$103 suggest routine tax/estate planning. Monitor next insider filings for any unplanned open-market sales.
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+1- T+0 · Nov 11 $105.81entry
- T+1 · 5d ago −0.01%α +0.34% · $105.80
- T+3 · todayOpen
- T+5 · tomorrow Pending
- T+20 · in 23d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Three Edwards Lifesciences insiders, including the CEO and a CVP, sold a total of $6.05M in open-market sales under 10b5-1 plans. The sales follow a strong Q3 earnings beat and raised guidance reported six days earlier. The dollar value is modest relative to the company's market cap, and the 10b5-1 plans indicate pre-arranged trading, reducing the signal.
Key Financial Metrics
Key Facts
- CEO Bernard Zovighian sold 23,100 shares (total $2.38M) under a 10b5-1 plan on Nov 9, 2026
- CVP Donald Bobo sold 48,900 shares ($5.04M) under a 10b5-1 plan on Nov 9, 2026
- CVP Daniel Lippis sold 619 shares ($65K) under a 10b5-1 plan on Nov 10, 2026
- Total open-market sales: $6.05M, all under 10b5-1 plans
- Sales occurred 6 days after Q3 2026 earnings beat (EPS $0.80 vs $0.74 consensus, revenue $1.72B vs $1.68B) and raised guidance
- Insiders also exercised derivatives at $72.68/share on Nov 9, acquiring shares at a discount before selling
Financial Impact
Total open-market sales of $6.05M, representing a small fraction of market cap (well under 0.1%)
Risk Factors
- Insider sales, though planned, could be perceived negatively by the market if volume increases
- CEO selling after a strong earnings beat may raise questions about future growth sustainability
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-EW-1794619318272 |
Track record
27 reports on EW
1 of 3 bullish or bearish reports moved the stock their way by T+5. Best: +4.94% at T+5 after the Nov 4, 2026 report. 3 of 3 went positive at some point.
Filters
- Nov 10, 20266d ago Insider Cluster Neutral 3/10 Viewing Entry $105.81 Now $107.11 +1.23% settles Nov 18
- Nov 10, 20266d ago Insider Cluster Neutral 2/10 Entry $105.81 Now $107.11 +1.23% settles Nov 18
- Nov 10, 20266d ago 144 Neutral 2/10 Entry $105.81 Now $107.11 +1.23% settles Nov 18
- Nov 9, 20267d ago Insider Cluster Neutral 2/10 Entry $104.01 Now $107.11 +2.98% settles Nov 17
- Nov 9, 20267d ago 144 Neutral 3/10 Entry $104.01 Now $107.11 +2.98% settles Nov 17
- Nov 9, 20267d ago 144 Neutral 2/10 Entry $104.01 Now $107.11 +2.98% settles Nov 17
- Nov 4, 202612d ago 8-K Bullish 6/10 Entry $100.82 to $105.80 Now $107.11 +6.24% ▲ +4.94% +1.65% vs SPY
- Oct 29, 202618d ago Institutional Cluster Neutral 3/10 Entry $94.44 to $100.82 Now $107.11 +13.42% ▲ +6.76% +11.48% vs SPY
- Aug 31, 202611w ago Insider Cluster Neutral 2/10 Entry $90.74 to $86.18 Now $107.11 +18.04% ▼ −5.03% −5.11% vs SPY
- Aug 28, 202611w ago Insider Cluster Neutral 2/10 Entry $90.75 to $86.72 Now $107.11 +18.03% ▼ −4.44% −4.30% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers